Toronto, Ontario and Haifa, Israel–(Newsfile Corp. – February 10, 2026) – NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company“), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion – Israel Institute of Technology. which evaluated multiple production batches of NurExone’s exosomes. The results support the Company’s Chemistry, Manufacturing and Controls (“CMC“) readiness by strengthening evidence of repeatable manufacturing and quality testing and represent an important step toward a potential Investigational New Drug (“IND“) application, the regulatory filing required to begin human clinical trials.
Batch-to-batch consistency is a core factor in biological production for clinical manufacturing. Four independent NurExone exosome production batches showed a highly consistent protein “fingerprint,” demonstrating the robustness and reproducibility of the Company’s manufacturing process.